Xilis believes cultivating micro-tumors may hold the key to more effective cancer treatments

Shen and Hsu have taken that research and advanced it, developing a process that can cultivate and sustain tumors from a cancer patient — allowing physicians and pharmaceutical companies to develop even more tailored treatments that can respond to the particular type of cancer.

“Already in clinical trials, we have data showing our technology can successfully predict treatment success and finding new therapy for drug resistant patients.”

While the near-term value of the company’s technology is in its ability to better target therapies for patients, longer term, there’s value in the data set that the company is amassing.

The potential to save pharmaceutical companies millions of dollars to do initial testing on how effective a treatment is can’t be overlooked, according to Shen.

Full Article